NASDAQ:SNDX - Get Free Report ) issued its quarterly earnings results on Wednesday. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.11, Briefing.com reports. During the same period last year, the firm posted ($0.59) earnings per share.
Get Syndax Pharmaceuticals alerts:
Sign Up
Syndax Pharmaceuticals Price Performance SNDX traded down $0.41 during trading on Thursday, reaching $21.97. 838,175 shares of the stock were exchanged, compared to its average volume of 1,116,099. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -7.53 and a beta of 1.01. Syndax Pharmaceuticals has a 1 year low of $11.22 and a 1 year high of $25.34. The business's 50 day moving average price is $22.47 and its two-hundred day moving average price is $20.16.
Wall Street Analyst Weigh In A number of research firms have recently issued reports on SNDX. StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a report on Friday, January 19th. HC Wainwright restated a "buy" rating and set a $41.00 price objective on shares of Syndax Pharmaceuticals in a research report on Thursday. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. Stifel Nicolaus increased their price target on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Citigroup lowered their price objective on Syndax Pharmaceuticals from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $34.42.
Check Out Our Latest Stock Analysis on Syndax Pharmaceuticals
About Syndax Pharmaceuticals (
Get Free Report )
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Read More
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
